---
title: "Tremfya (guselkumab), all indications: Drug interactions questions"
description: "Drug interactions questions on Tremfya (guselkumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Tremfya have drug interactions? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/tremfya/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab), all indications: Drug interactions questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)

## Drug interactions

<a id="tremfya-drug-interactions"></a>

### Does Tremfya have drug interactions?

> “The formation of CYP450 enzymes can be altered by increased levels of certain 
> cytokines (e.g., IL-1, IL-6, IL-10, TNFα, interferon) during chronic inflammation.
> Results from an exploratory drug-drug interaction trial in subjects with moderate-
> to-severe plaque psoriasis suggested a low potential for clinically relevant drug 
> interactions for drugs metabolized by CYP3A4, CYP2C9, CYP2C19 and CYP1A2 but 
> the interaction potential cannot be ruled out for drugs metabolized by CYP2D6. 
> However, the results were highly variable because of the limited number of 
> subjects in the trial.
> Upon initiation of TREMFYA in patients who are receiving concomitant CYP450 
> substrates, particularly those with a narrow therapeutic index, consider monitoring 
> for therapeutic effect or drug concentration and consider dosage adjustment as 
> needed [see Clinical Pharmacology (12.3)].”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

> “Population pharmacokinetic analyses indicated that concomitant use of NSAIDs, oral 
> corticosteroids and conventional DMARDs such as methotrexate (MTX), azathioprine 
> (AZA), and 6-mercaptopurine (6-MP), did not affect the clearance of guselkumab.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

## Related pages
- [Medical information: Tremfya (guselkumab): All indications](https://www.evicenter.com/medical-information/tremfya)
- [Indication](https://www.evicenter.com/medical-information/tremfya/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/tremfya/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/tremfya/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya/access-and-coverage)
